• 主题
高级搜索  >
历史搜索 清空历史
首页> 中文期刊> 《世界临床病例杂志》 >Almitrine for COVID-19 critically ill patients – a vascular therapy for a pulmonary vascular disease: Three case reports

Almitrine for COVID-19 critically ill patients – a vascular therapy for a pulmonary vascular disease: Three case reports

         
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND Several reports with clinical,histological and imaging data have observed the involvement of lung vascular function to explain the severe hypoxemia in coronavirus disease 2019(COVID-19)patients.It has been hypothesized that an increased pulmonary blood flow associated with an impairment of hypoxic pulmonary vasoconstriction is responsible for an intrapulmonary shunt.COVID-19 may lead to refractory hypoxemia(PaO_(2)/FiO_(2) ratio below 100 mmHg)despite mechanical ventilation and prone positioning.We hypothesized that the use of a pulmonary vasoconstrictor may help decrease the shunt and thus enhance oxygenation.CASE SUMMARY We report our experience with three patients with refractory hypoxemia treated with almitrine to enhance oxygenation.Low dose almitrine(Vectarion®;Servier,Suresnes,France)was started at an infusion rate of 4μg×kg/min on a central line.The PaO_(2)/FiO_(2) ratio and total respiratory system compliance during almitrine infusion were measured.For the three patients,the PaO_(2)/FiO_(2) ratio time-course showed a dramatic increase whereas total respiratory system compliance was unchanged.The three patients were discharged from the intensive care unit.The intensive care unit length of stay for patient 1,patient 2 and patient 3 was 30 d,32 d and 31 d,respectively.Weaning from mechanical ventilation was performed 13 d,18 d and 15 d after almitrine infusion for patient 1,2 and 3,respectively.We found no deleterious effects on the right ventricular function,which was similar to previous studies on almitrine safety.CONCLUSION Almitrine may be effective and safe to enhance oxygenation in coronavirus disease 2019 patients.Further controlled studies are required.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号